文献速递冠心病

中国中青年超高危ACS患者LDL-C水平与降脂治疗现状

[Low-density lipoprotein cholesterol levels and lipid-lowering treatment status among young and middle-aged ultra-high-risk patients with acute coronary syndrome in China].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2022-01-01

基于CCC-ACS项目纳入2014至2019年42 230例18~59岁ACS住院患者,其中86.9%符合超高危标准。超高危患者入院时LDL-C均值2.8±1.0 mmol/L,仅5.3%达到<1.4 mmol/L;院前降脂治疗率17.5%,多为他汀单药,接受他汀者中仅9.9%入院时LDL-C<1.4 mmol/L。

要点

  • 中青年ACS住院患者中86.9%符合超高危ASCVD标准。
  • 超高危患者入院时仅5.3%达到LDL-C<1.4 mmol/L目标。
  • 院前降脂治疗率仅17.5%,接受他汀者达标率9.9%。

核心结论

  • 中青年ACS住院患者绝大多数属于超高危,需要更低的LDL-C降脂治疗目标。
  • 超高危患者院前较少服用降胆固醇药物,大部分患者入院时LDL-C水平高于推荐目标值且差距较大。

研究设计与样本

  • 基于CCC-ACS项目,由中华医学会心血管病学分会与美国心脏协会合作开展。
  • 在全国159家三级医院和82家二级医院连续入选ACS住院患者并收集临床信息。
  • 纳入2014年11月至2019年12月登记的18~59岁ACS住院患者共42 230例。
  • 超高危按CSC《超高危动脉粥样硬化性心血管疾病患者血脂管理中国专家共识》标准界定。
  • 分析入院时LDL-C平均水平、院前调脂治疗情况及LDL-C达标比例。

主要发现

  • 42 230例患者年龄(50.4±6.9)岁,男性86.8%(36 676/42 230)。
  • 86.9%(36 687/42 230)符合超高危标准。
  • 超高危患者入院时LDL-C水平为(2.8±1.0)mmol/L,仅5.3%(1 948/36 687)达到LDL-C<1.4 mmol/L。
  • 超高危患者中17.5%(6 430/36 687)院前服用调脂药物,其中96.4%(6 198/6 430)为他汀单药治疗。
  • 接受院前他汀治疗者中仅9.9%(626/6 323)入院时LDL-C<1.4 mmol/L。

关键数值与推荐

  • 超高危界定依据CSC《超高危动脉粥样硬化性心血管疾病患者血脂管理中国专家共识》。
  • LDL-C目标值为<1.4 mmol/L。
  • 超高危患者入院时LDL-C均值(2.8±1.0)mmol/L,达标率5.3%(1 948/36 687)。
  • 院前调脂治疗率17.5%(6 430/36 687),他汀单药占96.4%(6 198/6 430)。
  • 接受他汀者入院时LDL-C<1.4 mmol/L比例为9.9%(626/6 323)。

临床怎么用

  • 对中青年ACS患者应常规按超高危ASCVD评估并设定LDL-C<1.4 mmol/L目标。
  • 关注院前降脂治疗不足,入院时评估LDL-C距目标差距并强化降脂方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To assess low-density lipoprotein cholesterol (LDL-C) levels and use of lipid-lowering treatment among young and middle-aged ultra-high-risk patients with acute coronary syndrome (ACS) in China. Methods: The study was based on the"Improving Care for Cardiovascular Disease in China (CCC)-ACS"project, a collaborative registry by and Chinese Society of Cardiology (CSC) and the American Heart Association. Hospitalized-patients with ACS were consecutively enrolled from 159 tertiary and 82 secondary hospitals across China, related clinical information was collected. This study included young and middle-aged hospitalized patients (18-59 years) with ACS from November 2014 to December 2019 registered in CCC-ACS project. Ultra-high-risk was defined according to Chinese expert consensus on lipid management of ultra-high-risk atherosclerotic cardiovascular disease (ASCVD) patients of CSC. The mean LDL-C levels at admission, pre-hospital lipid-lowering therapy and proportion of patients with LDL-C target achieved were analyzed. Results: A total of 42 230 patients younger than 60 years with ACS were included in this study. The mean age was (50.4±6.9) years, and 86.8% (36 676/42 230) of the ACS patients were male. Among them, 86.9% (36 687/42 230) met the criteria of ultra-high-risk. The mean level of LDL-C at admission was (2.8±1.0)mmol/L, only 5.3 % (1 948/36 687) patients achieved the targeted goal of LDL-C<1.4 mmol/L. Among the ultra-high-risk ASCVD patients, 17.5% (6 430/36 687) received lipid-lowering drugs before hospitalization, 96.4% (6 198/6 430) of whom received statins monotherapy. Among patients receiving pre-hospital statins, only 9.9% (626/6 323) patients reached an LDL-C<1.4 mmol/L at admission. Conclusions: The majority of young and middle-aged hospitalized patients with ACS are ultra-high-risk patients for ASCVD in China. Pre-hospital lipid-lowering drugs use is lower in these ultra-high-risk ASCVD patients and most patients do not reach the new LDL-C target level at admission. 目的: 了解中国中青年超高危急性冠状动脉综合征(ACS)患者低密度脂蛋白胆固醇(LDL-C)水平及降胆固醇药物使用现状。 方法: 本研究基于中华医学会心血管病学分会(CSC)和美国心脏协会(AHA)合作的中国心血管疾病医疗质量改善(CCC)项目。该项目在全国159家三级医院和82家二级医院连续入选ACS住院患者,系统收集患者临床相关信息。本研究纳入CCC项目2014年11月至2019年12月入选的中青年(年龄18~59岁)ACS住院患者,根据CSC《超高危动脉粥样硬化性心血管疾病患者血脂管理中国专家共识》超高危患者的界定标准,分析超高危ACS患者LDL-C平均水平及院前接受调脂治疗情况。 结果: 研究共纳入42 230例中青年ACS住院患者,年龄(50.4±6.9)岁,男性86.8%(36 676/42 230)。86.9%(36 687/42 230)的患者符合超高危标准。超高危ACS患者入院时LDL-C水平为(2.8±1.0)mmol/L,仅有5.3%(1 948/36 687)的患者达到1.4 mmol/L的目标值。超高危患者中,17.5%(6 430/36 687)的患者院前服用调脂药物,其中96.4%(6 198/6 430)的患者采用他汀单药治疗。接受他汀治疗的超高危患者中,9.9%(626/6 323)的患者LDL-C<1.4 mmol/L。 结论: 中青年ACS住院患者中绝大多数属于超高危,需要采用更低的LDL-C降脂治疗目标。超高危患者院前较少服用降胆固醇药物,大部分患者入院时LDL-C水平高于推荐的目标值且距目标值的差距较大。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Liu, Zhao, Hao, et al. [Low-density lipoprotein cholesterol levels and lipid-lowering treatment status among young and middle-aged ultra-high-risk patients with acute coronary syndrome in China]. Zhonghua Xin Xue Guan Bing Za Zhi. 2022. PMID: 36517436. doi:10.3760/cma.j.cn112148-20220920-00731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。